Associated Papers
Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma With Micropapillary Component.
Zhang S et al.
Frontiers in Oncology, 2021
34221970 (PubMed )
Supplement: Table_3.xlsx › Supplementary_Table_S3
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H et al.
Ebiomedicine, 2019
31668570 (PubMed )
Supplement: mmc4.xlsx › Sheet1
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.
Mahoney CL et al.
British Journal of Cancer, 2009
Select a paper to view details